Alnylam Pharmaceuticals (ALNY) Other Operating Expenses (2012 - 2026)

Alnylam Pharmaceuticals has reported Other Operating Expenses for 11 years, with the latest figure at $211.1 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 197.18% year-over-year to $211.1 million; the trailing twelve-month figure through Mar 2026 stood at $822.0 million (up 150.26% YoY), and the FY2025 full-year result was $681.9 million, up 110.86% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $211.1 million, down from $267.7 million in the prior quarter.
• The five-year high for Other Operating Expenses was $267.7 million in Q4 2025, with the low at $35.6 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $99.7 million across 5 years, with a median of $84.3 million in 2023.
• Annual changes were most pronounced in 2024 — Other Operating Expenses retreated 19.56% — and 2026, when it surged 197.18%.
• Alnylam Pharmaceuticals' Other Operating Expenses stood at $51.3 million in 2022, then jumped by 67.48% to $85.9 million in 2023, then increased by 19.75% to $102.8 million in 2024, then surged by 160.39% to $267.7 million in 2025, then retreated by 21.14% to $211.1 million in 2026.
• The last three Other Operating Expenses figures came in at $211.1 million (Q1 2026), $267.7 million (Q4 2025), and $200.2 million (Q3 2025), per Business Quant data.